Hong-yu Li, Ph.D., a researcher with the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences, has received a five-year, $1.27 million grant from the National Institutes of Health and the National Cancer Institute to work toward developing two treatment options for acute myeloid leukemia patients.
Li, a professor with the College of Pharmacy in the Pharmaceutics Department, leads the developmental therapeutics research program at the Cancer Institute.
The grant will fund a study called "Development of Potent, Selective, Non-Myelotoxic FLT3 Inhibitors that Retain Efficacy Against Common Mechanisms of Resistance." Li will serve as a principal investigator.
Also principal investigators are Dr. Neil Shah from the University of California at San Francisco and John Kuriyan, Ph.D., from the University of California at Berkeley.
